Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
- Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients[1]; EVALUATE-HF results complement findings[2]
- PROVE-HF establishes significant correlation between improvement in widely used cardiac biomarker and positive changes in heart structure and?ability to pump blood in patients taking Entresto[1]
- Safety and tolerability of Entresto were comparable to previously reported findings[1],[2],[3]
- Frequency of adverse events was generally consistent with PARADIGM-HF, with the exception of dizziness (16.8% in PROVE-HF vs. 6% in PARADIGM-HF)[1],[3].
- 65% of patients achieved the target dose of Entresto, 97/103 mg BID, at some point during the 52-week study[1].
- Frequency of positively adjudicated angioedema was low, occurring in only two patients (0.3%), which were resolved with antihistamines or no therapy[1].
- Left atrial volume index (-2.8 mL/m2; 95% CI: -4.0, -1.6)
- Mitral E/e? ratio (-1.8; 95% CI: -2.8, -0.8)
- Left ventricular end systolic volume index (-1.6 mL/m2; 95% CI: -3.1, -0.03)
- Left ventricular end diastolic volume index (-2.0 mL/m2; 95% CI: -3.7, -0.3)
- Frequency of adverse events was generally consistent with PARADIGM-HF and similar between treatment groups[2],[3].
- 83% of patients achieved the target dose of sacubitril/valsartan 97/103 mg BID[2].
- One positively-adjudicated angioedema case occurred in the enalapril treatment group[2].
- One death occurred in each treatment group during the double-blind 12-week period of the study[2].